| Business Summary | | Sonus
Pharmaceuticals
Inc.
is
engaged
in
the
research
and
development
of
therapeutic
drug
delivery
and
oxygen
delivery
products
utilizing
its
core
technology
in
emulsion
formulations
and
surfactant
chemistry.
Based
on
this
proprietary
core
technology,
the
Company
has
developed
the
TOCOSOL
drug
delivery
system
to
solubilize
therapeutic
drugs
that
are
poorly
soluble
in
water.
The
Company
is
developing
a
cancer
therapy
product
and
a
cardiovascular
therapy
product
using
the
TOCOSOL
technology.
The
Company
is
also
developing
an
oxygen
delivery
product
based
on
core
technology
that
utilizes
stabilized
fluorocarbon
gas
microbubbles
to
more
efficiently
transport
oxygen
to
body
tissues. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Sonus
Pharmaceuticals
is
engaged
in
the
research
and
development
of
therapeutic
drug
delivery
products
based
on
its
emulsion
formulation
technology.
For
the
six
months
ended
6/30/01,
revenues
rose
from
$45
thousand
to
$1.2
million.
Net
loss
rose
from
$94
thousand
to
$2.5
million.
Revenues
reflect
a
$1
million
ultrasound
contrast
patent
license
fee
payment
from
Chugai.
Net
loss
reflects
the
absence
of
$4.3
million
received
from
patent
litigation
and
insurance
settlements
in
the
prior
period. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Michael Martino, 45 Pres,
CEO, Director | $250K | Richard Klein, 38 CFO,
VP-Fin. | 146K | Nagesh Palepu Sr.
VP, CTO, Chief Scientific Officer | -- | John Flaherty, M.D., 59 Sr.
VP and CMO | -- | Gordon Brandt, M.D., 41 VP,
Clinical and Regulatory Affairs | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|